

Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?

<https://marketpublishers.com/r/B2F1E563672EN.html>

Date: November 2011

Pages: 47

Price: US\$ 595.00 (Single User License)

ID: B2F1E563672EN

Abstracts

Between now and 2019, a vast range of blockbuster drugs will go off patent, opening the floodgates in the EU to the biosimilars market. Already established there since 2006, biosimilars are set to be worth between \$2.25 billion and \$4.8 billion by 2015.

The potential is undeniable. Yet even in its advanced state compared to other regulated and unregulated markets, European biosimilars continue to be challenged by issues and hurdles, ranging from development and manufacturing to approval and opposition from originator companies. What lessons are there to be learned?

Report Overview

In *Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?*, FirstWord Dossier examines the emerging biosimilars market. The report, based on expert interviews and analysis, examines market differences across Europe and different therapeutic areas. The impact of biosimilars on originator companies—and their response—is discussed, as well as strategies biosimilar companies will engage in to expand their market share. And most importantly, the report offers insight into biosimilar deals and what the future holds in the EU.

Key features

Discussion of biosimilar markets in five geographic areas

Examination of key factors driving biosimilar uptake, including molecule and indications

Detailed overview of development, manufacturing and approval issues in Europe

Insight into the position and protectionism of originator companies

Reporting on the role of collaboration

Key Benefits

Access to firsthand opinions from experts in the biosimilars and biotechnology industry

Review of deal-making data in biosimilars from a deal-making market leader

Forward-looking analysis of the future of biosimilars

Key Questions Asked

What are the challenges facing biosimilars in Europe?

How can biosimilars companies take market share in Europe?

How can originator biologics companies keep market share in Europe?

Which companies are collaborating over biosimilars development?

What deals are being made?

What's next for biosimilars?

Who Should Read This Report

Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?

Market access directors and managers

Medical and scientific affairs professionals

Pricing and reimbursement teams

Intellectual property professionals

Patent analysts

Legal affairs teams

Regulatory and government affairs professionals

Key quotes

“The size of the global biologics market creates a massive opportunity for biosimilar developers to come in and take some of that market. The size of the prize in Europe will be significant, so there’s a big incentive for biosimilar companies to come in, develop these biosimilar products, and compete against the originator brands for market share.”

– Duncan Emerton, Head of Biosimilars, Datamonitor Healthcare Consulting

“I can't see the biosimilars market following the classic small molecule generic model where on day one, five molecules enter the market and the price drops to 20 percent of the brand. The economics just will not match those of the small molecule drugs.”

– Asa Cox, founder of biosimilarlicensing.com

“You can see that over time the biosimilar products have started to be accepted and used quite broadly in certain markets. There is a difference in uptake between countries – the uptake of biosimilars is not uniform across all the EU – and there is a difference between individual molecules as well.”

– Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing at Hospira

Expert Views

Carsten Thiel, Regional Vice President, Europe and Australia, Amgen

Paul Greenland, EMEA Director of Biosimilars and Proprietary Marketing at Hospira

Duncan Emerton, Head of Biosimilars, Datamonitor Healthcare Consulting

Asa Cox, Founder of biosimilarlicensing.com

Lee Coney, Chief Scientific Officer, Biologics, Huntingdon Life Sciences

Jim Furniss, Director, Global Market Access Strategy, Bridgehead International

Andrew Teuten, Senior Partner, Sagittarius IP

Contents

EXECUTIVE SUMMARY

BIOSIMILAR DRUGS IN EUROPE

WHAT ARE BIOSIMILARS?

Generics and biosimilars – similarities and differences

Biosimilars available so far in Europe

THE MARKET OPPORTUNITIES FOR BIOSIMILARS IN EUROPE

The biologics patent cliff will have an impact on the market

Market types for biosimilars will differ across Europe

Geographic markets for biosimilars will vary across Europe

In Italy, prescriptions are fulfilled by brand

In France and Spain, drugs are discounted to targets

In the UK, biosimilar uptake is driven by NICE

In Germany, biosimilars uptake is good but varies by drug type

Biosimilar uptake will vary by molecule and indication across Europe

Epoetin uptake may have been slowed by immunogenicity issues

Filgrastim uptake has been faster in Europe

Biosimilar use is likely to vary between chronic and episodic treatment

There may be a resistance to switching patients on established treatments

Hospital physicians may be more likely to use biosimilars than primary care physicians

Biosimilars will have an impact in cost-sensitive markets

The paediatric population may be reluctant to take up biosimilars

THE CHALLENGES FOR BIOSIMILARS IN EUROPE

The biosimilars challenge: Gaining approval in Europe

The EU regulatory process for biosimilars

Biosimilar regulations will be a steep learning curve

Will regulations be fair and balanced on all points?

The biosimilars challenge: Overcoming development and manufacturing hurdles

Biologics are highly variable by nature

Variations can cause issues with immunogenicity

The biosimilars challenge: Overcoming patent hurdles

The biosimilars challenge: Gaining stakeholder trust

Payers can be a major driver for biosimilars uptake

Physicians will be key gatekeepers for biologics and biosimilars

Patients may be cautious about biosimilars

THE DEFENSIVE POSITION: ORIGINATOR COMPANIES WILL TRY TO LIMIT BIOSIMILAR UPTAKE

Lifecycle management can maintain market share

Lack of automatic substitution will protect originator drugs

Exclusivity provisions and patents will protect originator drugs

Originator companies can exploit loyalty to maintain market share

Focusing on quality, safety and efficacy claims can maintain loyalty

Using marketing, sales and healthcare professional training to attract and keep market share

Protecting the market through degree of similarity – is a biosimilar really similar?

Competitive pricing and rebate agreements will keep cost-sensitive customers

THE OFFENSIVE POSITION: BREAKING INTO A NEW MARKET

Pricing is the key differentiator for biosimilars

Knowing the market will help gain market share

Information and education: defending biosimilars against the naysayers

Sales, marketing and account management: Market share through talking to the payers

Education for healthcare professionals: Market share through talking to the physicians

Gaining market share by adding value: Devices and formulations

Making the biosimilar easier to use: Devices

Making the biosimilar easier to handle: formulations

Protecting biosimilars through patents

THE COMPANY LANDSCAPE: OPPORTUNITIES FOR COMPANIES IN BIOSIMILARS

Generics companies will be key players

COLLABORATION AND LICENSING IN THE BIOSIMILARS MARKET

Collaborations between generics companies – bringing together development and

marketing

Collaborations between generic and originator companies combines know-how and manufacturing capabilities

Geographic collaborations allows access to wider markets

Looking into biosimilars deal data

- Biosimilar deals by volume

- Biosimilar deals by value

- Biosimilar deals by type

- Biosimilar deals by indication

Biosimilar deals: Deal case studies

- Biopharma company signs agreement to access biosimilars

- Generics company signs agreement to fill pipeline

WHAT'S NEXT FOR BIOSIMILARS IN EUROPE?

Monoclonal antibodies will be a dramatic entry to the biosimilars market

Biobetters could 'follow-on' from biosimilars

- Biobetters will follow a different route of approval

The US: Changing the biosimilars environment

CONCLUSION

ACKNOWLEDGEMENTS

BIBLIOGRAPHY

I would like to order

Product name: Biosimilar Drugs in Europe: Threat or Opportunity to Innovation?

Product link: <https://marketpublishers.com/r/B2F1E563672EN.html>

Price: US\$ 595.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B2F1E563672EN.html>